Cwm LLC Purchases 28,831 Shares of Moderna, Inc. (NASDAQ:MRNA)

CWM LLC grew its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 12.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 260,999 shares of the company's stock after purchasing an additional 28,831 shares during the period. CWM LLC owned about 0.07% of Moderna worth $7,399,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Sentry Investment Management LLC acquired a new stake in shares of Moderna in the first quarter worth $31,000. Deseret Mutual Benefit Administrators raised its holdings in shares of Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after buying an additional 392 shares during the last quarter. Crowley Wealth Management Inc. bought a new position in shares of Moderna in the fourth quarter valued at about $41,000. Itau Unibanco Holding S.A. raised its holdings in Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares during the last quarter. Finally, Vega Investment Solutions bought a new stake in Moderna during the 4th quarter worth about $45,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on MRNA shares. Cowen began coverage on Moderna in a research report on Sunday. They issued a "hold" rating for the company. Evercore ISI dropped their price objective on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Royal Bank Of Canada dropped their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. JPMorgan Chase & Co. reduced their target price on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a report on Thursday, May 22nd. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Moderna in a research note on Sunday. Four investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $46.61.

Moderna Trading Up 1.0%

Shares of NASDAQ:MRNA traded up $0.31 during mid-day trading on Thursday, hitting $32.37. 3,756,589 shares of the company traded hands, compared to its average volume of 8,885,009. The stock has a market cap of $12.52 billion, a P/E ratio of -3.71 and a beta of 1.84. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $126.42. The stock has a 50-day moving average price of $27.62 and a two-hundred day moving average price of $31.05.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. The business had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The business's revenue was down 35.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($3.07) earnings per share. As a group, analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.